NO3049208T3 - - Google Patents

Info

Publication number
NO3049208T3
NO3049208T3 NO14741534A NO14741534A NO3049208T3 NO 3049208 T3 NO3049208 T3 NO 3049208T3 NO 14741534 A NO14741534 A NO 14741534A NO 14741534 A NO14741534 A NO 14741534A NO 3049208 T3 NO3049208 T3 NO 3049208T3
Authority
NO
Norway
Application number
NO14741534A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3049208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3049208T3 publication Critical patent/NO3049208T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO14741534A 2012-12-14 2014-06-30 NO3049208T3 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
NO3049208T3 true NO3049208T3 (OSRAM) 2018-04-14

Family

ID=50934967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14741534A NO3049208T3 (OSRAM) 2012-12-14 2014-06-30

Country Status (11)

Country Link
US (3) US9822347B2 (OSRAM)
EP (2) EP2931265B3 (OSRAM)
JP (2) JP6345690B2 (OSRAM)
AU (3) AU2013359179B2 (OSRAM)
CA (1) CA2894539C (OSRAM)
DK (2) DK2931265T6 (OSRAM)
ES (2) ES2862335T3 (OSRAM)
FI (1) FI2931265T6 (OSRAM)
NO (1) NO3049208T3 (OSRAM)
PT (2) PT2931265T (OSRAM)
WO (1) WO2014093690A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011207381B2 (en) * 2010-01-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
ES2862335T3 (es) 2012-12-14 2021-10-07 Univ Leland Stanford Junior Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
US20200289613A1 (en) * 2017-11-04 2020-09-17 Aravive Biologics, Inc. Methods of treating metastatic cancers using axl decoy receptors
WO2023039254A1 (en) * 2021-09-11 2023-03-16 Aravive Inc Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030166110A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
JP2006524496A (ja) 2003-04-18 2006-11-02 ノバルティス アクチエンゲゼルシャフト 骨関節炎の診断および処置のためのチロシンキナーゼを標的化する方法および組成物
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (en) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Mer diagnostic and therapeutic agents
WO2006118308A1 (ja) 2005-05-02 2006-11-09 Toray Industries, Inc. 食道ガン及び食道ガン転移診断のための組成物及び方法
US8168415B2 (en) * 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
WO2008128072A2 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
CA2747678A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
KR20120035145A (ko) * 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
AU2011207381B2 (en) * 2010-01-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US10844106B2 (en) 2010-11-08 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
ES2862335T3 (es) * 2012-12-14 2021-10-07 Univ Leland Stanford Junior Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
WO2015030849A1 (en) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2909669C (en) * 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
JP6345690B2 (ja) 2018-06-20
ES2665323T3 (es) 2018-04-25
ES2665323T7 (es) 2023-06-15
CA2894539A1 (en) 2014-06-19
AU2017272193A1 (en) 2017-12-21
EP2931265B1 (en) 2018-01-31
US11136563B2 (en) 2021-10-05
US9822347B2 (en) 2017-11-21
EP2931265A1 (en) 2015-10-21
DK2931265T6 (da) 2023-05-01
EP3326622B1 (en) 2021-01-20
HK1256071A1 (en) 2019-09-13
US20220220458A1 (en) 2022-07-14
DK3326622T3 (da) 2021-04-06
DK2931265T3 (en) 2018-04-16
AU2019210662B2 (en) 2021-07-01
EP2931265A4 (en) 2016-08-31
US20150315553A1 (en) 2015-11-05
AU2013359179B2 (en) 2017-10-05
JP2016510309A (ja) 2016-04-07
PT2931265T (pt) 2018-04-16
WO2014093690A1 (en) 2014-06-19
PT3326622T (pt) 2021-04-07
EP2931265B3 (en) 2023-04-05
AU2013359179A1 (en) 2015-07-02
US20180030422A1 (en) 2018-02-01
JP2018154641A (ja) 2018-10-04
ES2862335T3 (es) 2021-10-07
JP6832887B2 (ja) 2021-02-24
FI2931265T6 (fi) 2023-05-23
AU2019210662A1 (en) 2019-08-22
EP3326622A1 (en) 2018-05-30
CA2894539C (en) 2021-09-28

Similar Documents

Publication Publication Date Title
BR112014017635A2 (OSRAM)
BR112014017614A2 (OSRAM)
BR112014017625A2 (OSRAM)
BR112014017659A2 (OSRAM)
BR112014017646A2 (OSRAM)
BR112014018648A2 (OSRAM)
BR112014017638A2 (OSRAM)
AR092201A1 (OSRAM)
BR112013027865A2 (OSRAM)
BR112014017634A2 (OSRAM)
BR112014017644A2 (OSRAM)
BR112014017647A2 (OSRAM)
BR112014013184A8 (OSRAM)
BR112014017623A2 (OSRAM)
BR112014017652A2 (OSRAM)
BR112014017630A2 (OSRAM)
BR112014017627A2 (OSRAM)
BR112014017621A2 (OSRAM)
BR112014017631A2 (OSRAM)
BR112014017641A2 (OSRAM)
BR112014017622A2 (OSRAM)
NO3049208T3 (OSRAM)
BR112014017671A2 (OSRAM)
BR112014017636A2 (OSRAM)
BR112014017667A2 (OSRAM)